Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS (NCT03905707)

🧪 Interventions in This Study

• glepaglutide (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (27 Sites)

Showing the first 25 of 27 sites.

• Georgetown University Medical Center — Washington D.C., District of Columbia
• University of Chicago Children's Hospital — Chicago, Illinois
• Mayo Clinic College of Medicine — Rochester, Minnesota
• University of Nebraska Medical Center — Omaha, Nebraska
• Mount Sinai Hospital — New York, New York
• Cleveland Clinic — Cleveland, Ohio
• Vanderbilt University Medical Center, Nashville — Nashville, Tennessee
• UZ Leuven — Leuven,
• The Royal Alexandra Hospital — Edmonton,
• Western University — London,
• University Health Network - Toronto General Hospital — Toronto,
• Rigshospitalet — Copenhagen,
• Hôpital Beaujon — Clichy,
• Centre Hospitalier Lyon-Sud — Pierre-Bénite,
• Charité - Universitätsmedizin Berlin — Berlin,
• Universitätsklinikum Bonn — Bonn,
• Universitätsklinikum Frankfurt - Med. Klinik I — Frankfurt,
• Asklepios Kliniken Hamburg GmbH — Hamburg,
• Universitätsmedizin Rostock — Rostock,
• UMC Radboud Nijmegen — Nijmegen,
• Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi — Lodz,
• Solumed — Poznan,
• Szpital Skawina sp. z o.o. im. Stanley Dudricka — Skawina,
• St Mark's Hospital — Harrow,
• UCLH Foundation NHS Trust — London,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Short Bowel Syndrome

• Registry for Participants With Short Bowel Syndrome — Lexington, Massachusetts
• Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial — Washington D.C., District of Columbia
• Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome — Cleveland, Ohio
• Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. — Los Angeles, California
• A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome — Palo Alto, California

Explore by condition: All Short Bowel Syndrome clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.